About Champions Oncology (NASDAQ:CSBR)
Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans. The TOS segment provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. Its TumorGraft Technology Platform consists of processes, physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from patients that it has preserved for implantation in mice, along with the patient data and molecular information associated with the tumors, are known as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company's TumorBank.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E Ratio-9.42857142857143
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$15.41 million
Price / Sales2.82
Price / CashN/A
Book Value$0.04 per share
Price / Book99.00
Return on Equity-593.68%
Return on Assets-64.57%
Champions Oncology (NASDAQ:CSBR) Frequently Asked Questions
What is Champions Oncology's stock symbol?
Champions Oncology trades on the NASDAQ under the ticker symbol "CSBR."
How were Champions Oncology's earnings last quarter?
Champions Oncology Inc (NASDAQ:CSBR) announced its earnings results on Thursday, December, 7th. The biotechnology company reported ($0.01) earnings per share for the quarter. The biotechnology company had revenue of $5.20 million for the quarter. Champions Oncology had a negative net margin of 26.26% and a negative return on equity of 593.68%. View Champions Oncology's Earnings History.
Who are some of Champions Oncology's key competitors?
Some companies that are related to Champions Oncology include Novelion Therapeutics (NVLN), OncoSec Medical (ONCS), Brainstorm Cell Therapeutics (BCLI), Senomyx (SNMX), Navidea Biopharmaceuticals (NAVB), Abzena (ABZA), NovaBay Pharmaceuticals (NBY), CytRx (CYTR), Vernalis (VER), Immutep (IMMP), Cleveland BioLabs (CBLI), Caladrius Biosciences (CLBS), OvaScience (OVAS), AEterna Zentaris (AEZS), ReNeuron Group (RENE), Scancell (SCLP), Oncobiologics (ONS) and Can Fite Biopharma (CANF).
Who are Champions Oncology's key executives?
Champions Oncology's management team includes the folowing people:
- Joel Ackerman, Chairman of the Board (Age 51)
- Ronnie Morris M.D., President, Chief Executive Officer, Director (Age 49)
- David Miller CPA, Vice President - Finance (Age 46)
- Philip Breitfeld, Chief Strategic and Innovation Officer, Director (Age 63)
- David Sidransky M.D., Lead Independent Director (Age 56)
- Daniel N. Mendelson, Independent Director (Age 52)
- Abba David Poliakoff, Independent Director (Age 64)
- Scott R. Tobin, Independent Director (Age 45)
How do I buy Champions Oncology stock?
Shares of Champions Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Champions Oncology's stock price today?
One share of Champions Oncology stock can currently be purchased for approximately $3.96.
How big of a company is Champions Oncology?
Champions Oncology has a market capitalization of $43.51 million and generates $15.41 million in revenue each year. The biotechnology company earns $-6,880,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. Champions Oncology employs 79 workers across the globe.
How can I contact Champions Oncology?
Champions Oncology's mailing address is One University Plaza Suite 307, Hackensack NJ, 07601. The biotechnology company can be reached via phone at 201-808-8400 or via email at [email protected]
MarketBeat Community Rating for Champions Oncology (CSBR)MarketBeat's community ratings are surveys of what our community members think about Champions Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Champions Oncology (NASDAQ:CSBR) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Champions Oncology (NASDAQ:CSBR) Earnings History and Estimates Chart
Champions Oncology (NASDAQ CSBR) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|12/7/2017||Q2 2018||($0.01)||$5.20 million||View||Listen|
|9/14/2017||Q1 2018||($0.06)||$5.03 million||View||N/A|
|7/27/2017||Q4 2017||($0.22)||$3.72 million||View||N/A|
|3/16/2017||Q3 2017||($0.13)||$3.57 million||View||N/A|
|11/29/2016||Q2 2017||($0.05)||$4.46 million||View||N/A|
|3/15/2016||Q316||($0.21)||$1.80 million||$2.60 million||View||Listen|
Champions Oncology (NASDAQ:CSBR) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Champions Oncology (NASDAQ:CSBR)
No dividend announcements for this company have been tracked by MarketBeat.com
Champions Oncology (NASDAQ CSBR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 44.30%
Institutional Ownership Percentage: 38.04%
Champions Oncology (NASDAQ CSBR) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|10/21/2016||Ronnie Morris||President||Buy||30,000||$1.66||$49,800.00||1,091,347|| |
|10/19/2016||Ronnie Morris||President||Buy||10,000||$1.70||$17,000.00||1,081,347|| |
|10/18/2016||Joel Ackerman||CEO||Buy||2,000||$1.70||$3,400.00||1,043,266|| |
|10/14/2016||Joel Ackerman||CEO||Buy||7,300||$1.67||$12,191.00||1,035,466|| |
|10/14/2016||Ronnie Morris||President||Buy||10,305||$1.66||$17,106.30||1,061,347|| |
|10/13/2016||Ronnie Morris||President||Buy||29,695||$1.67||$49,590.65||1,041,347|| |
|10/10/2016||Ronnie Morris||President||Buy||9,537||$1.66||$15,831.42||1,026,347|| |
|10/7/2016||Joel Ackerman||CEO||Buy||8,202||$1.63||$13,369.26||1,027,764|| |
|9/23/2016||Joel Ackerman||CEO||Buy||33||$1.65||$54.45||1,026,764|| |
|9/21/2016||Joel Ackerman||CEO||Buy||5,000||$1.66||$8,300.00||1,022,731|| |
|9/20/2016||Ronnie Morris||President||Buy||3,000||$1.58||$4,740.00||1,021,810|| |
|3/11/2015||Michael Maurice Brown||Major Shareholder||Buy||6,250,000||$0.40||$2,500,000.00|| |
|3/20/2014||Daniel Newman Mendelson||Director||Buy||100,000||$1.08||$108,000.00|| |
|3/19/2014||Ronnie Morris||President||Buy||100,000||$1.07||$107,000.00|| |
|1/28/2013||Michael Maurice Brown||Major Shareholder||Buy||7,000,000||$0.50||$3,500,000.00|| |
|1/28/2013||Ronnie Morris||President||Buy||500,000||$0.50||$250,000.00|| |
Champions Oncology (NASDAQ CSBR) News Headlines
Champions Oncology (NASDAQ:CSBR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Champions Oncology (NASDAQ:CSBR) Income Statement, Balance Sheet and Cash Flow Statement
Champions Oncology (NASDAQ CSBR) Stock Chart for Monday, January, 22, 2018